Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.53 |
| ▸ | CAMK2A | Q9UQM7 | 7/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | THRA | P10827 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7391266 | 0.88 | DGAT1 (0.54) | DGAT1CAMK2AESR2MMEACE | |
| SCHEMBL15822666 | 0.88 | DGAT1 (0.54) | DGAT1NR1H4MMEACE | |
| SCHEMBL2238912 | 0.85 | CAMK2A (0.59) | CAMK2ACA2THRATHRB | |
| SCHEMBL4936502 | 0.79 | RXRA (0.47) | CAMK2AESR2CA2NR1H4HSD17B1 | |
| SCHEMBL4943817 | 0.79 | HSD17B1 (0.58) | CAMK2AESR2CA2HSD17B1 | |
| SCHEMBL4943843 | 0.79 | RXRA (0.63) | DGAT1CAMK2ACA2THRATHRB | |
| SCHEMBL8024134 | 0.76 | MME (0.50) | DGAT1ESR2MMEACE | |
| SCHEMBL29419329 | 0.76 | CHRM1 (0.57) | — | |
| SCHEMBL260512 | 0.76 | CHRM1 (0.57) | — | |
| SCHEMBL31225898 | 0.75 | SENP1 (0.45) | DGAT1CAMK2AESR2THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | DGAT1 120/4885CAMK2A 942/4885ESR2 135/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | DGAT1 2743/4885CAMK2A 2270/4885ESR2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.